These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29720711)

  • 1. In Vitro and In Vivo Characterization of PCC0104005, a Novel Modulator of Serotonin-Dopamine Activity, as an Atypical Antipsychotic Drug.
    Xu Y; Zhu X; Wang H; Sun S; Yue X; Tian J
    Sci Rep; 2018 May; 8(1):6892. PubMed ID: 29720711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.
    Maeda K; Sugino H; Akazawa H; Amada N; Shimada J; Futamura T; Yamashita H; Ito N; McQuade RD; Mørk A; Pehrson AL; Hentzer M; Nielsen V; Bundgaard C; Arnt J; Stensbøl TB; Kikuchi T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):589-604. PubMed ID: 24947465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and Pharmacology of the enantiomers of the potential atypical antipsychotic agents 5-OMe-BPAT and 5-OMe-(2,6-di-OMe)-BPAT.
    Homan EJ; Copinga S; Unelius L; Jackson DM; Wikström HV; Grol CJ
    Bioorg Med Chem; 1999 Jul; 7(7):1263-71. PubMed ID: 10465402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isoquinolinone derivatives as potent CNS multi-receptor D
    Jin J; Zhang K; Dou F; Hao C; Zhang Y; Cao X; Gao L; Xiong J; Liu X; Liu BF; Zhang G; Chen Y
    Eur J Med Chem; 2020 Dec; 207():112709. PubMed ID: 32877805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antipsychotic-like effects in rodents of YQA31 involve dopamine D3 and 5-HT1A receptor.
    Gou HY; Sun X; Li F; Wang ZY; Wu N; Su RB; Cong B; Li J
    Pharmacol Rep; 2017 Dec; 69(6):1125-1130. PubMed ID: 29128790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: relevance for antipsychotic action.
    López-Gil X; Artigas F; Adell A
    Int J Neuropsychopharmacol; 2009 May; 12(4):487-99. PubMed ID: 18752722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel benzothiazolin-2-one and benzoxazin-3-one arylpiperazine derivatives with mixed 5HT1A/D2 affinity as potential atypical antipsychotics.
    Taverne T; Diouf O; Depreux P; Poupaert JH; Lesieur D; Guardiola-Lemaître B; Renard P; Rettori MC; Caignard DH; Pfeiffer B
    J Med Chem; 1998 Jun; 41(12):2010-8. PubMed ID: 9622542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orally active benzamide antipsychotic agents with affinity for dopamine D2, serotonin 5-HT1A, and adrenergic alpha1 receptors.
    Reitz AB; Baxter EW; Codd EE; Davis CB; Jordan AD; Maryanoff BE; Maryanoff CA; McDonnell ME; Powell ET; Renzi MJ; Schott MR; Scott MK; Shank RP; Vaught JL
    J Med Chem; 1998 Jun; 41(12):1997-2009. PubMed ID: 9622541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.
    Brindisi M; Butini S; Franceschini S; Brogi S; Trotta F; Ros S; Cagnotto A; Salmona M; Casagni A; Andreassi M; Saponara S; Gorelli B; Weikop P; Mikkelsen JD; Scheel-Kruger J; Sandager-Nielsen K; Novellino E; Campiani G; Gemma S
    J Med Chem; 2014 Nov; 57(22):9578-97. PubMed ID: 25343529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of 5-HT7 receptor antagonism in the amelioration of MK-801-induced learning and memory deficits by the novel atypical antipsychotic drug lurasidone.
    Horisawa T; Nishikawa H; Toma S; Ikeda A; Horiguchi M; Ono M; Ishiyama T; Taiji M
    Behav Brain Res; 2013 May; 244():66-9. PubMed ID: 23376699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone.
    Martin P; Waters N; Schmidt CJ; Carlsson A; Carlsson ML
    J Neural Transm (Vienna); 1998; 105(4-5):365-96. PubMed ID: 9720968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of the halogen bonding on D
    Partyka A; Kurczab R; Canale V; Satała G; Marciniec K; Pasierb A; Jastrzębska-Więsek M; Pawłowski M; Wesołowska A; Bojarski AJ; Zajdel P
    Bioorg Med Chem; 2017 Jul; 25(14):3638-3648. PubMed ID: 28529043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-aminotetralin-derived substituted benzamides with mixed dopamine D2, D3, and serotonin 5-HT1A receptor binding properties: a novel class of potential atypical antipsychotic agents.
    Homan EJ; Copinga S; Elfström L; van der Veen T; Hallema JP; Mohell N; Unelius L; Johansson R; Wikström HV; Grol CJ
    Bioorg Med Chem; 1998 Nov; 6(11):2111-26. PubMed ID: 9881101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of MK-801-induced heat shock protein 72/73 in rat brain by antipsychotic and monoaminergic agents targeting D2, 5-HT1A, 5-HT2A and α1-adrenergic receptors.
    Romón T; Planas AM; Adell A
    CNS Neurol Disord Drug Targets; 2014 Feb; 13(1):104-11. PubMed ID: 24040788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel 4-alkyl-1-arylpiperazines and 1,2,3,4-tetrahydroisoquinolines containing diphenylmethylamino or diphenylmethoxy fragment with differentiated 5-HT1A/5-HT2A/D2 receptor activity.
    Paluchowska MH; Mokrosz MJ; Charakchieva-Minol S; Duszyńska B; Kozioł A; Wesołowska A; Stachowicz K; Chojnacka-Wójcik E
    Pol J Pharmacol; 2003; 55(4):543-52. PubMed ID: 14581712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone.
    Horisawa T; Ishibashi T; Nishikawa H; Enomoto T; Toma S; Ishiyama T; Taiji M
    Behav Brain Res; 2011 Jun; 220(1):83-90. PubMed ID: 21277905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformationally constrained butyrophenones with mixed dopaminergic (D(2)) and serotoninergic (5-HT(2A), 5-HT(2C)) affinities: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo- and -thienocycloalkanones as putative atypical antipsychotics.
    Raviña E; Negreira J; Cid J; Masaguer CF; Rosa E; Rivas ME; Fontenla JA; Loza MI; Tristán H; Cadavid MI; Sanz F; Lozoya E; Carotti A; Carrieri A
    J Med Chem; 1999 Jul; 42(15):2774-97. PubMed ID: 10425088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.
    Ishibashi T; Horisawa T; Tokuda K; Ishiyama T; Ogasa M; Tagashira R; Matsumoto K; Nishikawa H; Ueda Y; Toma S; Oki H; Tanno N; Saji I; Ito A; Ohno Y; Nakamura M
    J Pharmacol Exp Ther; 2010 Jul; 334(1):171-81. PubMed ID: 20404009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.